|
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer. |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst) |
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro |
|
|
Honoraria - Novartis; Roche; Seagen |
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Puma Biotechnology; Roche/Genentech; Seagen |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Celldex (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Philips Healthcare (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Zenith Epigenetics (Inst) |
Travel, Accommodations, Expenses - Eisai; GP Pharm; Grunenthal; Novartis; Pierre Fabre; Roche |
|
|
Employment - Institute of Cancer Research |
Honoraria - Astellas Pharma; Lilly |
Consulting or Advisory Role - Boehringer Ingelheim; Janssen; Novartis; Phoenix Solutions |
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - Bayer; Sierra Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche |
|
|
Honoraria - Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics |
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen |
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical |
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kyocera (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
Employment - AstraZeneca/MedImmune; Azeria therapeutics (I) |
Leadership - Azeria Therapeutics (I) |
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Azeria Therapeutics (I) |
Honoraria - AstraZeneca (I) |
Consulting or Advisory Role - Azeria Therapeutics (I) |
Research Funding - AstraZeneca (I) |
Patents, Royalties, Other Intellectual Property - Patent: Anti-cxc chemokine receptor-2 binding molecules and uses thereof; Patent: Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia; Royalties from Active Motif (I) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
|
|
No Relationships to Disclose |